Europe Moving To Restrict Sovaldi’s Indication To Curb Its Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe is having problems stomaching the high price of Gilead's hepatitis C cure, Sovaldi, which could be why some EU countries are severely restricting its indication.